Getting a better view on liver cancer
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of protein induced vitamin K absence or antagonist-II (PIVKA-II) in serum. The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Lumipulse® G PIVKA-II Immunoreaction Cartridges:
- Art. no. 233184 (3 x 14 Tests - CE) - This product is not available in the USA and in Canada.
Lumipulse® G PIVKA-II Calibrators Set:
- Art. no. 233191 (2 x 3 x 1.5 ml - CE) - This product is not available in the USA and in Canada.
Allows stratification of patients on transplant waiting list.
Predicts recurrence of HCC.
Complementary to AFP for improved detection of (early) HCC.
Only assay available on an automated platform (LUMIPULSE G1200)
Oncology menu available for routine, specialized and unique markers
Calibrators and controls available
Different clinical applications
Monitoring: Correlation with microvascular invasion, recurrence and tumor size
Diagnosis: Complementary to AFP for the improved detection of HCC
CLEIA - ChemiLuminescent Enzyme Immunoassay
Test principle: Two-Step sandwich assay
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high rate of mortality and an increasing incidence. The most common causes of HCC are either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis). The starting point in the diagnostic surveillance of at risk patients is ultrasound. In a second stage this can be completed with the measurement of a tumor marker called α-fetoprotein (AFP). Since ultrasound has a poor performance in cirrhotic patients and is also operator dependent, further characterization by CT or MRI is often required. As it is important to detect HCC at an early stage when the disease is still curable, biomarkers can complete the diagnosis obtained with ultrasound before moving on to the more expensive MRI. Biomarkers can also be used to better stratify patients on the liver transplant waiting list. Additionally, the risk of recurrence of HCC after transplantation can be assessed by monitoring patients with biomarkers.